The observed dose-response relationship between baseline BMI and age with cardiovascular efficacy aligns with recent trials showing that GLP-1 RAs may be especially effective in populations at elevated metabolic and cardiovascular risk such as those who have obesity and CVD. The gene discussed is GLP1R; the disease is obesity disorder.